1 / 44

Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation 2012

Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation 2012. Summary Slides. SUM12_1.ppt. Location of Centers Participating in the CIBMTR 2012. Slide 2. SUM12_22.ppt. Transplant Activity in the U.S. 1980-2011. Transplants. Slide 3. SUM12_23.ppt.

lorin
Download Presentation

Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation 2012

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation2012 Summary Slides SUM12_1.ppt

  2. Location of Centers Participating in the CIBMTR2012 Slide 2 SUM12_22.ppt

  3. Transplant Activity in the U.S.1980-2011 Transplants Slide 3 SUM12_23.ppt

  4. Allogeneic Stem Cell Sourcesby Recipient Age2001-2010 Transplants, % Age £ 20 yrs Age > 20 yrs Slide 4 SUM12_24.ppt

  5. Autologous Stem Cell Sourcesby Recipient Age, 2001-2010 Transplants, % Age £ 20 yrs Age > 20 yrs Slide 5 SUM12_25.ppt

  6. Trends in Transplantsby Type and Recipient Age*2001-2010 Transplants, % Allogeneic TransplantsAutologous Transplants * Transplants for AML, ALL, NHL, Hodgkin Disease, Multiple Myeloma Slide 6 SUM12_26.ppt

  7. Trends in Transplantsby Transplant Type and Recipient Age*1990-2010 Transplants, % Allogeneic TransplantsAutologous Transplants * Transplants for AML, ALL, NHL, Hodgkin Disease, Multiple Myeloma Slide 7 SUM12_27.ppt

  8. Indications for Hematopoietic Stem Cell Transplants in the United States, 2010(Inflation factor: Auto=1.25 (80%), Allo=1.05 (95%), All Transplants) Number of Transplants Slide 8 SUM12_28.ppt

  9. Indications for Hematopoietic Stem Cell Transplants for Age £ 20yrs, in the U.S., 2010(Inflation factor: Auto=1.25 (80%), Allo=1.05 (95%), All Transplants) Number of Transplants Slide 9 SUM12_29.ppt

  10. Allogeneic Transplants for Age £ 20yrs,Registered with the CIBMTR, 1993-2010- by Donor Type and Graft Source - Number of Transplants Slide 10 SUM12_30.ppt

  11. Allogeneic Transplants for Age > 20yrs,Registered with the CIBMTR, 1993-2010- by Donor Type and Graft Source - Number of Transplants Slide 11 SUM12_31.ppt

  12. Unrelated Donor Stem Cell Sourcesby Recipient Age2001-2010 Transplants, % Age £ 20 yrs Age > 20 yrs Slide 12 SUM12_32.ppt

  13. Unrelated Cord Blood Transplants by AgeRegistered with the CIBMTR2001-2010 Number of Transplants * * Data incomplete Slide 13 SUM12_33.ppt

  14. One-year Survivalby Year of Transplant, Donor and Age, Worldwide, 1997-2010- In any remission, Acute Leukemia, CML or MDS- One-Year Survival, % Slide 14 SUM12_34.ppt

  15. 100-day Mortality after Autologous Transplants, 2010 Mortality, % Slide 15 SUM12_35.ppt

  16. 100-day Mortality after HLA-identical Sibling Transplants,2010 Early Disease Intermediate Disease Advanced Disease Chronic Phase Accelerated Phase Blast Phase Other Mortality, % Slide 16 SUM12_36.ppt

  17. 100-day Mortality after Unrelated Donor Transplants,2008-2009 Early Disease Intermediate Disease Advanced Disease Chronic Phase Accelerated Phase Blast Phase Other Mortality, % Slide 17 SUM12_37.ppt

  18. Causes of Death after Transplants Done in2009-2010 HLA-identical Sibling Primary Disease (49%) New Malignancy (1%) GVHD (16%) Unrelated Donor Infection (13%) Primary Disease (37%) New Malignancy (1%) Organ Failure (5%) Other (16%) GVHD (18%) Autologous Primary Disease (72%) New Malignancy (1%) Infection (7%) Infection (18%) Other (18%) Organ Failure (3%) Organ Failure (8%) Other (17%) Slide 18 SUM12_38.ppt

  19. Allogeneic TransplantsRegistered with the CIBMTR, 2001-2010 - by Conditioning Regimen Intensity & Age - Number of Transplants * * Data incomplete Slide 19 SUM12_39.ppt

  20. Allogeneic Transplants after Reduced-intensity Conditioning, by Donor Type, Registered with CIBMTR1998-2010 Number of Transplants Slide 20 SUM12_40.ppt

  21. Percentage of Reduced Intensity Conditioning Allo-HCTs, Registered with CIBMTR, 1998-2010- by Year of Transplant & Disease - One-Year Survival, % Slide 21 SUM12_41.ppt

  22. Indications for Hematopoietic Stem Cell Transplants for Age ³ 50yrs, in the U.S., 2010 Number of Transplants Slide 22 SUM12_42.ppt

  23. Allogeneic Transplants in the U.S.,Registered with the CIBMTR, 2007-2011 - by Donor Type - Transplants, % Slide 23 SUM12_43.ppt

  24. Hematopoietic Cell Transplant Comorbid Index of U.S. Transplant Recipientsby Group Age2008-2011 Transplants, % Slide 24 SUM12_44.ppt

  25. Probability of Survival after HLA-identical Sibling Donor Transplants for AML, 2000-2010- By Disease Status - 100 100 90 90 80 80 70 70 60 60 Early (N=7,210) Probability of Survival, % 50 50 40 40 Intermediate (N=1,906) 30 30 20 20 Advanced (N=2,923) 10 10 P < 0.0001 0 0 1 3 0 2 4 5 6 Years Slide 25 SUM12_2.ppt

  26. Probability of Survival after Unrelated Donor Transplants for AML, 2000-2010- By Disease Status - 100 100 90 90 80 80 70 70 60 60 Probability of Survival, % 50 50 Early (N=5,364) 40 40 Intermediate (N=3,374) 30 30 20 20 Advanced (N=3.702) 10 10 P < 0.0001 0 0 1 3 0 2 4 5 6 Years Slide 26 SUM12_3.ppt

  27. Survival after HLA-identical Sibling Donor Transplants for AML, Age <20 yrs, 2000-2010- by Disease Status - 100 100 90 90 80 80 70 70 Early (N=1,292) 60 60 Probability of Survival, % 50 50 Intermediate (N=268) 40 40 30 30 Advanced (N=270) 20 20 10 10 P < 0.0001 0 0 1 3 0 2 4 5 6 Years Slide 27 SUM12_4.ppt

  28. Probability of Survival after Autologous Transplants for AML, 2000-2010- by Disease Status - 100 100 90 90 80 80 70 70 60 60 Intermediate (N=735) Probability of Survival, % 50 50 40 40 Early (N=2,139) 30 30 20 20 Advanced (N=152) 10 10 P < 0.0001 0 0 1 3 0 2 4 5 6 Years Slide 28 SUM12_5.ppt

  29. Probability of Survival after Allogeneic Transplants for MDS, 2000-2010- by Disease Status and Donor Type - 100 100 90 90 80 80 70 70 Early, sibling donor (N=750) 60 60 Early, unrelated donor (N=890) Probability of Survival, % 50 50 40 40 Advanced, unrelated donor (N=1,660) 30 30 20 20 Advanced, sibling donor (N=1,407) 10 10 P < 0.0001 0 0 1 3 0 2 4 5 6 Years Slide 29 SUM12_6.ppt

  30. Survival after HLA-identical Sibling Donor Transplants for ALL, Age < 20 yrs,2000-2010- by Disease Status - 100 100 90 90 80 80 70 70 Early (N=849) 60 60 Probability of Survival, % 50 50 Intermediate (N=1,203) 40 40 30 30 20 20 Advanced (N=210) 10 10 P < 0.0001 0 0 1 3 0 2 4 5 6 Years Slide 30 SUM12_7.ppt

  31. Probability of Survival after Unrelated Donor Transplants for ALL, Age < 20 yrs, 2000-2010- By Disease Status - 100 100 90 90 80 80 70 70 Early (N=977) 60 60 Probability of Survival, % 50 50 40 40 Intermediate (N=2,034) 30 30 20 20 Advanced (N=289) 10 10 P < 0.0001 0 0 1 3 0 2 4 5 6 Years Slide 31 SUM12_8.ppt

  32. Survival after HLA-identical Sibling Donor Transplants for ALL, Age ³ 20 yrs, 2000-2010- By Disease Status - 100 100 90 90 80 80 70 70 60 60 Early (N=2,214) Probability of Survival, % 50 50 40 40 Intermediate (N=715) 30 30 20 20 Advanced (N=584) 10 10 P < 0.0001 0 0 1 3 0 2 4 5 6 Years Slide 32 SUM12_9.ppt

  33. Probability of Survival after Unrelated Donor Transplants for ALL, Age ³ 20 yrs, 2000-2010- By Disease Status - 100 100 90 90 80 80 70 70 60 60 Early (N=1,818) Probability of Survival, % 50 50 40 40 30 30 Intermediate (N=1,075) 20 20 10 10 Advanced (N=767) P < 0.0001 0 0 1 3 0 2 4 5 6 Years Slide 33 SUM12_10.ppt

  34. Probability of Survival after HLA-identical Sibling Donor Transplants for CML, 1998-2010- By Disease Status and Transplant Year - 100 100 90 90 80 80 CP, 2001-2010 (N=2,498) 70 70 CP, 1998-2000 (N=2,239) 60 60 AP, 2001-2010 (N=360) Probability of Survival, % 50 50 40 40 AP, 1998-2000 (N=291) 30 30 20 20 10 10 P < 0.0001 0 0 1 3 0 2 4 5 6 Years Slide 34 SUM12_11.ppt

  35. Survival after Autologous and HLA-matched Sibling Donor Hematopoietic Cell Transplants for CLL, 2000-2010- by Donor Type and Conditioning Regimen Intensity - 100 100 90 90 Autologous transplant (N=270) 80 80 70 70 60 60 Probability of Survival, % 50 50 Myeloablativeconditioning (N=450) 40 40 Reduced-intensity conditioning (N=871) 30 30 20 20 10 10 P < 0.0001 0 0 1 3 0 2 4 5 6 Years Slide 35 SUM12_12.ppt

  36. Probability of Survival after Allogeneic Transplants for SAA, 2000-2010- By Donor Type and Age - 100 100 £ 20y, Sibling Donor (N=1,375) 90 90 80 80 > 20y, Sibling Donor (N=1,425) 70 70 £ 20y, Unrelated Donor (N=654) 60 60 > 20y, Unrelated Donor (N=634) Probability of Survival, % 50 50 40 40 30 30 20 20 10 10 P < 0.0001 0 0 1 3 0 2 4 5 6 Years Slide 36 SUM12_13.ppt

  37. Probability of Survival after Autologous Transplants for Hodgkin Disease, 2000-2010- By Disease Status - 100 100 90 90 CR (N=2,907) 80 80 70 70 60 60 Not in CR, sensitive (N=3,832) Probability of Survival, % 50 50 Not in CR, resistant (N=1,237) 40 40 30 30 20 20 10 10 P < 0.0001 0 0 1 3 0 2 4 5 6 Years Slide 37 SUM12_14.ppt

  38. Probability of Survival after Allogeneic Transplants for Hodgkin Disease, 2000-2010- By Conditioning Regimen and Donor Type - 100 100 90 90 80 80 70 70 60 60 Probability of Survival, % 50 50 Sibling Donor (N=356) 40 40 30 30 Unrelated Donor (N=205) 20 20 10 10 P = 0.226 0 0 1 3 0 2 4 5 6 Years Slide 38 SUM12_15.ppt

  39. Survival after Autologous Transplants for Follicular Lymphoma, 2000-2010- By Disease Status - 100 100 90 90 80 80 Sensitive (N=2,676) 70 70 60 60 Probability of Survival, % 50 50 Resistant (N=279) 40 40 30 30 20 20 10 10 P < 0.0001 0 0 1 3 0 2 4 5 6 Years Slide 39 SUM12_16.ppt

  40. Probability of Survival after Allogeneic and HLA-identical Sibling Transplants for Follicular Lymphoma, 2000-2010- By Disease Status - 100 100 90 90 80 80 Sensitive (N=840) 70 70 60 60 Probability of Survival, % 50 50 Resistant (N=212) 40 40 30 30 20 20 10 10 P = 0.002 0 0 1 3 0 2 4 5 6 Years Slide 40 SUM12_17.ppt

  41. Probability of Survival after Autologous Transplants for Diffuse Large B-Cell Lymphoma, 2000-2010- By Disease Status - 100 100 90 90 80 80 70 70 Sensitive (N=8,891) 60 60 Probability of Survival, % 50 50 40 40 30 30 Resistant (N=1,033) 20 20 10 10 P < 0.0001 0 0 1 3 0 2 4 5 6 Years Slide 41 SUM12_18.ppt

  42. Probability of Survival after HLA-identical Sibling Transplants for Diffuse Large B-Cell Lymphoma, 2000-2010- By Disease Status - 100 100 90 90 80 80 70 70 60 60 Probability of Survival, % 50 50 Sensitive (N=503) 40 40 30 30 20 20 Resistant (N=219) 10 10 P < 0.0001 0 0 1 3 0 2 4 5 6 Years Slide 42 SUM12_19.ppt

  43. Probability of Survival after Transplants for Mantle Cell Lymphoma, 2000-2010- By Donor Type - 100 100 90 90 80 80 70 70 Autologous (3,173) 60 60 Probability of Survival, % 50 50 Sibling donor (N=554) 40 40 30 30 Unrelated donor (N=389) 20 20 10 10 P < 0.0001 0 0 1 3 0 2 4 5 6 Years Slide 43 SUM12_20.ppt

  44. Probability of Survival after Transplants for Multiple Myeloma, 2000-2010- By Donor Type - 100 100 90 90 80 80 Autologous (N27,979) 70 70 60 60 Probability of Survival, % 50 50 40 40 Sibling Donor (N=892) 30 30 20 20 Unrelated donor (N=380) 10 10 P < 0.0001 0 0 1 3 0 2 4 5 6 Years Slide 44 SUM12_21.ppt

More Related